Single User License
INR 98070
Site License
INR 196140
Corporate User License
INR 294210

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Immune Pharmaceuticals Inc.-Product Pipeline Review-2015

Immune Pharmaceuticals Inc.-Product Pipeline Review-2015


  • Products Id :- GMDHC07276CDB
  • |
  • Pages: 47
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Immune Pharmaceuticals Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Immune Pharmaceuticals Inc.-Product Pipeline Review-2015', provides an overview of the Immune Pharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Immune Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Immune Pharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Immune Pharmaceuticals Inc.'s pipeline products

Reasons To Buy

Evaluate Immune Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Immune Pharmaceuticals Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Immune Pharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Immune Pharmaceuticals Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Pharmaceuticals Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Immune Pharmaceuticals Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immune Pharmaceuticals Inc. Snapshot 5

Immune Pharmaceuticals Inc. Overview 5

Key Information 5

Key Facts 5

Immune Pharmaceuticals Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Immune Pharmaceuticals Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Combination Treatment Modalities 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Immune Pharmaceuticals Inc.-Pipeline Products Glance 14

Immune Pharmaceuticals Inc.-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Immune Pharmaceuticals Inc.-Early Stage Pipeline Products 16

IND/CTA Filed Products/Combination Treatment Modalities 16

Preclinical Products/Combination Treatment Modalities 17

Immune Pharmaceuticals Inc.-Drug Profiles 18

(amitriptyline + ketamine hydrochloride) 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

bertilimumab 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

crolibulin 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

lidocaine hydrochloride 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

F-573 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Ferritizumab 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody Conjugate to Antagonize EGFR for Non-Small Cell Lung Cancer 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody Conjugate to Antagonize HER2 for Solid Tumors 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibody Conjugate to Antagonize HER3 for Solid Tumors 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Immune Pharmaceuticals Inc.-Pipeline Analysis 32

Immune Pharmaceuticals Inc.-Pipeline Products by Target 32

Immune Pharmaceuticals Inc.-Pipeline Products by Route of Administration 34

Immune Pharmaceuticals Inc.-Pipeline Products by Molecule Type 35

Immune Pharmaceuticals Inc.-Pipeline Products by Mechanism of Action 36

Immune Pharmaceuticals Inc.-Recent Pipeline Updates 37

Immune Pharmaceuticals Inc.-Dormant Projects 43

Immune Pharmaceuticals Inc.-Discontinued Pipeline Products 44

Discontinued Pipeline Product Profiles 44

histamine dihydrochloride 44

verubulin 44

Immune Pharmaceuticals Inc.-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

Immune Pharmaceuticals Inc., Key Information 5

Immune Pharmaceuticals Inc., Key Facts 5

Immune Pharmaceuticals Inc.-Pipeline by Indication, 2015 7

Immune Pharmaceuticals Inc.-Pipeline by Stage of Development, 2015 9

Immune Pharmaceuticals Inc.-Monotherapy Products in Pipeline, 2015 10

Immune Pharmaceuticals Inc.-Combination Treatment Modalities in Pipeline, 2015 11

Immune Pharmaceuticals Inc.-Partnered Products in Pipeline, 2015 12

Immune Pharmaceuticals Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

Immune Pharmaceuticals Inc.-Phase II, 2015 14

Immune Pharmaceuticals Inc.-Phase I, 2015 15

Immune Pharmaceuticals Inc.-IND/CTA Filed, 2015 16

Immune Pharmaceuticals Inc.-Preclinical, 2015 17

Immune Pharmaceuticals Inc.-Pipeline by Target, 2015 33

Immune Pharmaceuticals Inc.-Pipeline by Route of Administration, 2015 34

Immune Pharmaceuticals Inc.-Pipeline by Molecule Type, 2015 35

Immune Pharmaceuticals Inc.-Pipeline Products by Mechanism of Action, 2015 36

Immune Pharmaceuticals Inc.-Recent Pipeline Updates, 2015 37

Immune Pharmaceuticals Inc.-Dormant Developmental Projects,2015 43

Immune Pharmaceuticals Inc.-Discontinued Pipeline Products, 2015 44

Immune Pharmaceuticals Inc., Other Locations 45

Immune Pharmaceuticals Inc., Subsidiaries 45

List of Figures

Immune Pharmaceuticals Inc.-Pipeline by Top 10 Indication, 2015 7

Immune Pharmaceuticals Inc.-Pipeline by Stage of Development, 2015 9

Immune Pharmaceuticals Inc.-Monotherapy Products in Pipeline, 2015 10

Immune Pharmaceuticals Inc.-Partnered Products in Pipeline, 2015 12

Immune Pharmaceuticals Inc.-Pipeline by Top 10 Target, 2015 32

Immune Pharmaceuticals Inc.-Pipeline by Top 10 Route of Administration, 2015 34

Immune Pharmaceuticals Inc.-Pipeline by Top 10 Molecule Type, 2015 35

Immune Pharmaceuticals Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Immune Pharmaceuticals Inc.; Immune Pharmaceuticals Inc. - Key Therapeutics; Immune Pharmaceuticals Inc. - Pipeline Overview and Promising Molecules; Immune Pharmaceuticals Inc. - News; Immune Pharmaceuticals Inc. - Latest Updates; Immune Pharmaceuticals Inc. - Pipeline; Immune Pharmaceuticals Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com